201 related articles for article (PubMed ID: 16524323)
1. Evaluation of the rabbit Purkinje fibre assay as an in vitro tool for assessing the risk of drug-induced torsades de pointes in humans.
Aubert M; Osterwalder R; Wagner B; Parrilla I; Cavero I; Doessegger L; Ertel EA
Drug Saf; 2006; 29(3):237-54. PubMed ID: 16524323
[TBL] [Abstract][Full Text] [Related]
2. Choice of cardiac tissue plays an important role in the evaluation of drug-induced prolongation of the QT interval in vitro in rabbit.
Lu HR; Vlaminckx E; Teisman A; Gallacher DJ
J Pharmacol Toxicol Methods; 2005; 52(1):90-105. PubMed ID: 15978848
[TBL] [Abstract][Full Text] [Related]
3. The canine Purkinje fiber: an in vitro model system for acquired long QT syndrome and drug-induced arrhythmogenesis.
Gintant GA; Limberis JT; McDermott JS; Wegner CD; Cox BF
J Cardiovasc Pharmacol; 2001 May; 37(5):607-18. PubMed ID: 11336111
[TBL] [Abstract][Full Text] [Related]
4. Proarrhythmic effects of the class III agent almokalant: importance of infusion rate, QT dispersion, and early afterdepolarisations.
Carlsson L; Abrahamsson C; Andersson B; Duker G; Schiller-Linhardt G
Cardiovasc Res; 1993 Dec; 27(12):2186-93. PubMed ID: 8313427
[TBL] [Abstract][Full Text] [Related]
5. Safety of non-antiarrhythmic drugs that prolong the QT interval or induce torsade de pointes: an overview.
De Ponti F; Poluzzi E; Cavalli A; Recanatini M; Montanaro N
Drug Saf; 2002; 25(4):263-86. PubMed ID: 11994029
[TBL] [Abstract][Full Text] [Related]
6. Action potential experiments complete hERG assay and QT-interval measurements in cardiac preclinical studies.
Ducroq J; Printemps R; Guilbot S; Gardette J; Salvetat C; Le Grand M
J Pharmacol Toxicol Methods; 2007; 56(2):159-70. PubMed ID: 17604185
[TBL] [Abstract][Full Text] [Related]
7. Preclinical in vitro cardiac electrophysiology: a method of predicting arrhythmogenic potential of antihistamines in humans?
Cavero I; Mestre M; Guillon JM; Heuillet E; Roach AG
Drug Saf; 1999; 21 Suppl 1():19-31; discussion 81-7. PubMed ID: 10597865
[TBL] [Abstract][Full Text] [Related]
8. Nonclinical proarrhythmia models: predicting Torsades de Pointes.
Lawrence CL; Pollard CE; Hammond TG; Valentin JP
J Pharmacol Toxicol Methods; 2005; 52(1):46-59. PubMed ID: 15975832
[TBL] [Abstract][Full Text] [Related]
9. Prediction of the risk of Torsade de Pointes using the model of isolated canine Purkinje fibres.
Champeroux P; Viaud K; El Amrani AI; Fowler JS; Martel E; Le Guennec JY; Richard S
Br J Pharmacol; 2005 Feb; 144(3):376-85. PubMed ID: 15655517
[TBL] [Abstract][Full Text] [Related]
10. A new biomarker--index of cardiac electrophysiological balance (iCEB)--plays an important role in drug-induced cardiac arrhythmias: beyond QT-prolongation and Torsades de Pointes (TdPs).
Lu HR; Yan GX; Gallacher DJ
J Pharmacol Toxicol Methods; 2013; 68(2):250-259. PubMed ID: 23337247
[TBL] [Abstract][Full Text] [Related]
11. Sensitivity and Specificity of the In Vitro Guinea Pig Papillary Muscle Action Potential Duration for the Assessment of Drug-Induced Torsades De Pointes Liability in Humans.
Ducroq J
Handb Exp Pharmacol; 2015; 229():205-19. PubMed ID: 26091641
[TBL] [Abstract][Full Text] [Related]
12. Beat-by-beat QT interval variability, but not QT prolongation per se, predicts drug-induced torsades de pointes in the anaesthetised methoxamine-sensitized rabbit.
Jacobson I; Carlsson L; Duker G
J Pharmacol Toxicol Methods; 2011; 63(1):40-6. PubMed ID: 20451633
[TBL] [Abstract][Full Text] [Related]
13. In-vitro experimental models for the risk assessment of antibiotic-induced QT prolongation.
Lu HR; Vlaminckx E; Van de Water A; Rohrbacher J; Hermans A; Gallacher DJ
Eur J Pharmacol; 2006 Dec; 553(1-3):229-39. PubMed ID: 17054943
[TBL] [Abstract][Full Text] [Related]
14. In-vitro experimental models for the risk assessment of antibiotic-induced QT prolongation.
Lu HR; Vlaminckx E; Van de Water A; Rohrbacher J; Hermans A; Gallacher DJ
Eur J Pharmacol; 2007 Dec; 577(1-3):222-32. PubMed ID: 18074444
[TBL] [Abstract][Full Text] [Related]
15. ILSI-HESI cardiovascular safety subcommittee initiative: evaluation of three non-clinical models of QT prolongation.
Hanson LA; Bass AS; Gintant G; Mittelstadt S; Rampe D; Thomas K
J Pharmacol Toxicol Methods; 2006; 54(2):116-29. PubMed ID: 16843688
[TBL] [Abstract][Full Text] [Related]
16. Electrophysiological characterization of the prokinetic agents cisapride and mosapride in vivo and in vitro: implications for proarrhythmic potential?
Carlsson L; Amos GJ; Andersson B; Drews L; Duker G; Wadstedt G
J Pharmacol Exp Ther; 1997 Jul; 282(1):220-7. PubMed ID: 9223557
[TBL] [Abstract][Full Text] [Related]
17. QT interval prolongation and cardiac risk assessment for novel drugs.
Picard S; Lacroix P
Curr Opin Investig Drugs; 2003 Mar; 4(3):303-8. PubMed ID: 12735231
[TBL] [Abstract][Full Text] [Related]
18. The isolated rabbit heart and Purkinje fibers as models for identifying proarrhythmic liability.
Roche M; Renauleaud C; Ballet V; Doubovetzky M; Guillon JM
J Pharmacol Toxicol Methods; 2010; 61(3):238-50. PubMed ID: 20117224
[TBL] [Abstract][Full Text] [Related]
19. Review of the predictive value of the Langendorff heart model (Screenit system) in assessing the proarrhythmic potential of drugs.
Valentin JP; Hoffmann P; De Clerck F; Hammond TG; Hondeghem L
J Pharmacol Toxicol Methods; 2004; 49(3):171-81. PubMed ID: 15172013
[TBL] [Abstract][Full Text] [Related]
20. A rabbit Langendorff heart proarrhythmia model: predictive value for clinical identification of Torsades de Pointes.
Lawrence CL; Bridgland-Taylor MH; Pollard CE; Hammond TG; Valentin JP
Br J Pharmacol; 2006 Dec; 149(7):845-60. PubMed ID: 17031389
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
